The recovery strategies to support cervical cancer elimination in lower-and middle-income countries (LMICs) following COVID-19 disruptions
- PMID: 37455756
- PMCID: PMC10307672
- DOI: 10.1016/j.pmedr.2023.102291
The recovery strategies to support cervical cancer elimination in lower-and middle-income countries (LMICs) following COVID-19 disruptions
Abstract
The COVID-19 pandemic has exacerbated the existing challenges to achieving the WHO target of eliminating cervical cancer as a public health problem by working towards the target of fewer than four cases per 100 000 women. We reviewed the literature to identify potential recovery strategies to support cervical cancer prevention programs in lower-and middle-income countries (LMICs) following COVID-19 disruptions and the extent to which strategies have been implemented. Utilising the WHO health systems framework, we mapped these recovery strategies against the six building blocks to examine their reach across the health system. Most recovery strategies were focused on service delivery, while leadership and governance played a pivotal role in the continuity of cervical cancer prevention programs during the pandemic. Leadership and governance were the drivers for outcomes in the building blocks of health information systems, financing and critical support in operationalising service delivery strategies. In the aftermath of the COVID-19 pandemic with strained health resources and economies, stakeholders would significantly influence the coverage and sustainability of cervical cancer prevention programs. The support from multisectoral stakeholders would accelerate the recovery of cervical cancer prevention programs. To achieve the WHO target by 2030, we call for future studies to understand the barriers and facilitators from the perspectives of stakeholders in order to support the decision-making processes and information required to implement recovery strategies in LMICs.
© 2023 Published by Elsevier Inc.
Conflict of interest statement
This is a research project initiated by the research team and supported by Merck education grant. Merck has no financial interest, ownership, and intellectual property rights of the research project findings. SMG is supported by NHMRC APP1197951 Leadership Investigator grant level 3, a member of the advisory board for the nine valent HPV vaccine of Merck, received educational grant from Merck for study on HPV and young women through her institution and received Merck lecture fees. SK has served in advisory boards of both Merck & GSK and has received Merck lecture fees. IIP has received Roche lecture fees. DAM has received lecture fees from MSD. The other author reports no conflict of interest. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
References
-
- Bruni L., Serrano B., Roura E., Alemany L., Cowan M., Herrero R., Poljak M., Murillo R., Broutet N., Riley L.M., de Sanjose S. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. The Lancet Global Health. 2022;10(8):e1115–e1127. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
